BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/24/2022 12:41:49 PM | Browse: 572 | Download: 1335
 |
Received |
|
2022-01-05 18:04 |
|
Peer-Review Started |
|
2022-01-05 18:06 |
|
First Decision by Editorial Office Director |
|
2022-02-15 00:10 |
|
Return for Revision |
|
2022-02-15 00:10 |
|
Revised |
|
2022-04-01 09:13 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2022-05-05 03:14 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2022-05-07 00:44 |
|
Articles in Press |
|
2022-05-07 00:44 |
|
Edit the Manuscript by Language Editor |
|
2022-05-03 00:07 |
|
Typeset the Manuscript |
|
2022-05-13 08:19 |
|
Publish the Manuscript Online |
|
2022-05-24 12:41 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Andrea Pretta, Dario Spanu, Stefano Mariani, Nicole Liscia, Pina Ziranu, Valeria Pusceddu, Marco Puzzoni, Elena Massa, Mario Scartozzi and Eleonora Lai |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mario Scartozzi, MD, Chairman, Full Professor, Medical Oncology Unit, University Hospital and University of Cagliari, SS 554, bivio per Sestu, km 4,500, Monserrato 09042, Cagliari, Italy. marioscartozzi@gmail.com, Monserrato 09042, Cagliari, Italy. marioscartozzi@gmail.com |
| Key Words |
Metastatic pancreatic ductal adenocarcinoma; Palliative chemotherapy; Real-world data; Molecular selection; Biomarkers; Second-line treatment |
| Core Tip |
The present letter is intended to contribute to the collection of data on pancreatic ductal adenocarcinoma (PDAC) treatments in second-line settings through our experience with the promising data of efficacy and safety of a small group of study patients treated with second-line liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin. We also focused on highlighting the subgroups of PDAC patients who might benefit from target treatments, such as a small proportion of mutated BRCAs, and to identify comorbidities or characteristics that impact the prognosis of PDAC patients through our retrospective analysis that demonstrate a correlation between type II diabetes mellitus and improved overall survival. |
| Publish Date |
2022-05-24 12:41 |
| Citation |
Pretta A, Spanu D, Mariani S, Liscia N, Ziranu P, Pusceddu V, Puzzoni M, Massa E, Scartozzi M, Lai E. How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world. World J Clin Oncol 2022; 13(5): 417-422 |
| URL |
https://www.wjgnet.com/2218-4333/full/v13/i5/417.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v13.i5.417 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
